Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regenxbio Inc
(NQ:
RGNX
)
11.93
-0.38 (-3.09%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regenxbio Inc
< Previous
1
2
3
4
5
Next >
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
RegenXBio Posts Updated Data From Hunter Syndrome Gene Therapy Trial
February 09, 2022
Regenxbio Inc (NASDAQ: RGNX) announced
Via
Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
February 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Expert Ratings For Regenxbio
January 28, 2022
Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
Earnings Scheduled For November 2, 2021
November 02, 2021
Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •...
Via
Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, & More
February 06, 2022
Biotech stocks managed to close the week with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid some big pharma earnings. The sector came...
Via
Talk Markets
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...
Via
Benzinga
RegenXbio's Duchenne Gene Therapy Secures FDA Orphan Drug Tag
November 22, 2021
The FDA has granted Orphan Drug Designation to RegenXbio Inc's (NASDAQ: RGNX) RGX-202, potential one-time gene therapy for Duchenne muscular dystrophy (...
Via
Benzinga
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021
December 15, 2021
Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE:
Via
Benzinga
70 Biggest Movers From Yesterday
November 16, 2021
Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The...
Via
Benzinga
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
November 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded...
Via
Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...
Via
Benzinga
Barron's Latest Picks And Pans: Alleghany, Blade Air Mobility, Gene Therapy Picks And More
November 06, 2021
This weekend's Barron's cover story examines the bubbles in cryptocurrency, meme stocks and non-fungible tokens. Other featured articles discuss the stocks powering 2021...
Via
Benzinga
REGENXBIO inc (RGNX) Q3 2021 Earnings Call Transcript
November 03, 2021
RGNX earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
November 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...
Via
Benzinga
Exposures
COVID-19
Earnings Outlook For Regenxbio
November 01, 2021
Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Tuesday, 2021-11-02. Here's what investors need to know before the announcement. Analysts estimate...
Via
Benzinga
Regenxbio Reveals Interim Data From Diabetic Retinopathy Gene Therapy Trial
October 11, 2021
Regenxbio Inc (NASDAQ: RGNX) announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy (DR) without center-involved diabetic...
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
October 10, 2021
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets...
Via
Talk Markets
Exposures
Product Safety
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
October 10, 2021
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive...
Via
Benzinga
Exposures
Product Safety
44 Biggest Movers From Yesterday
October 05, 2021
Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares climbed 101.9% to close at $31.50 on Monday after the company announced its phase 2 study of XEN1101 for the treatment of...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
October 04, 2021
Gainers Progenity (NASDAQ:PROG) stock moved upwards by 18.43% to $2.12 during Monday's regular session. Trading volume for this security as of 12:30 EST is 91.5...
Via
Benzinga
30 Stocks Moving In Monday's Mid-Day Session
October 04, 2021
Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares jumped 71.1% to $26.69 after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all...
Via
Benzinga
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
October 03, 2021
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
October 01, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...
Via
Benzinga
Exposures
Product Safety
Could AbbVie's New Collaboration Be a Blockbuster?
September 27, 2021
AbbVie recently announced a strategic partnership with Regenxbio for wet age-related macular degeneration and diabetic retinopathy treatment.
Via
The Motley Fool
Why AbbVie Just Made a $1.8 Billion Gene Therapy Deal
September 25, 2021
The big drugmaker wants another near-term growth driver.
Via
The Motley Fool
Looking Into Regenxbio's Return On Capital Employed
September 15, 2021
Regenxbio (NASDAQ:RGNX) brought in sales totaling $22.04 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 18.58%, resulting in a loss of $...
Via
Benzinga
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal
September 14, 2021
Gene therapy is set to become one of the most vital spaces with high prospects in the biotech sector.
Via
Talk Markets
72 Biggest Movers From Yesterday
September 14, 2021
Gainers aTyr Pharma, Inc. (NASDAQ: LIFE) jumped 67% to settle at $9.15 on Monday as the company announced positive results from its Phase 1b/2a trial evaluating its lead...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.